AU3734900A - Method of promoting myocyte proliferation and myocardial tissue repair - Google Patents

Method of promoting myocyte proliferation and myocardial tissue repair Download PDF

Info

Publication number
AU3734900A
AU3734900A AU37349/00A AU3734900A AU3734900A AU 3734900 A AU3734900 A AU 3734900A AU 37349/00 A AU37349/00 A AU 37349/00A AU 3734900 A AU3734900 A AU 3734900A AU 3734900 A AU3734900 A AU 3734900A
Authority
AU
Australia
Prior art keywords
seq
group
tyr
ile
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU37349/00A
Other languages
English (en)
Inventor
Gere Dizerega
Kathleen Rodgers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU3734900A publication Critical patent/AU3734900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/30—Hormones
    • C12N2501/32—Angiotensins [AT], angiotensinogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU37349/00A 1999-03-09 2000-03-09 Method of promoting myocyte proliferation and myocardial tissue repair Abandoned AU3734900A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US12367899P 1999-03-09 1999-03-09
US60123678 1999-03-09
US15187499P 1999-08-31 1999-08-31
US60151874 1999-08-31
PCT/US2000/006198 WO2000053211A2 (en) 1999-03-09 2000-03-09 Method of promoting myocyte proliferation and myocardial tissue repair

Publications (1)

Publication Number Publication Date
AU3734900A true AU3734900A (en) 2000-09-28

Family

ID=26821778

Family Applications (1)

Application Number Title Priority Date Filing Date
AU37349/00A Abandoned AU3734900A (en) 1999-03-09 2000-03-09 Method of promoting myocyte proliferation and myocardial tissue repair

Country Status (4)

Country Link
EP (1) EP1158997A2 (de)
AU (1) AU3734900A (de)
CA (1) CA2364484A1 (de)
WO (1) WO2000053211A2 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6589938B2 (en) * 2001-06-29 2003-07-08 National University Of Singapore Use of angiotensin I derivatives as an agent for the treatment and prevention of infarction-related cardiac injuries and disorders
PL211654B1 (pl) 2002-10-08 2012-06-29 Rinat Neuroscience Corp Przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego, zastosowanie tego przeciwciała do wytwarzania leku do leczenia bólu pooperacyjnego i kompozycja farmaceutyczna zawierająca przeciwciało skierowane przeciwko NGF do zastosowania w leczeniu bólu pooperacyjnego
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
SI2263692T1 (sl) 2002-12-24 2020-10-30 Rinat Neuroscience Corp. Anti-NGF protitelesa in postopki, v katerih se le-ta uporabljajo
AU2004213044A1 (en) 2003-02-19 2004-09-02 Rinat Neuroscience Corp. Methods for treating pain by administering a nerve growth factor antagonist and an NSAID and compositions containing the same
AP2006003670A0 (en) 2003-12-23 2006-06-30 Rinat Neuroscience Corp Agonist anti-TRKC antibodies and methods using same
DK2206728T3 (en) 2004-04-07 2018-04-23 Rinat Neuroscience Corp METHODS OF TREATING BONE CANCER PAIN BY SUBMITTING A NERVOUS FACTOR-ANTAGONISTIC ANTIBODY
ME00419B (me) 2005-11-14 2011-10-10 Rinat Neuroscience Corp Antigonistička antitijela usmjerena protiv kalcitonita, peptida povezanog sa genom i postupkom njihovog korišćenja
US8591898B2 (en) 2007-12-17 2013-11-26 Pfizer Limited Treatment of interstitial cystitis
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Ｐｃｓｋ９拮抗劑類
WO2010086828A2 (en) 2009-02-02 2010-08-05 Rinat Neuroscience Corporation Agonist anti-trkb monoclonal antibodies
US20100234827A1 (en) * 2009-03-13 2010-09-16 Sigg Daniel C Method of treating heart failure
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
AR080291A1 (es) 2010-02-24 2012-03-28 Rinat Neuroscience Corp Anticuerpos antagonistas anti receptor de il-7 y procedimientos
JP5932670B2 (ja) 2010-03-11 2016-06-08 ライナット ニューロサイエンス コーポレイション ｐＨ依存性の抗原結合を有する抗体
AU2012282130B2 (en) 2011-07-14 2017-06-22 Pfizer Inc. Treatment with anti-PCSK9 antibodies
CN104053672A (zh) 2011-11-11 2014-09-17 瑞纳神经科学公司 Trop-2特异性抗体及其用途
WO2013093693A1 (en) 2011-12-22 2013-06-27 Rinat Neuroscience Corp. Staphylococcus aureus specific antibodies and uses thereof
RU2014123030A (ru) 2011-12-22 2016-02-20 Ринат Ньюросайенс Корп. Антагонистические антитела против человеческого рецептора гормона роста и способы их применения
EP3539982A3 (de) 2011-12-23 2020-01-15 Pfizer Inc Konstante regionen gentechnisch hergestellter antikörper für stellenspezifische konjugation sowie verfahren und verwendungen dafür
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
CA3208188A1 (en) 2013-03-15 2014-09-25 Takeda Pharmaceutical Company Limited Anti-plasma kallikrein antibodies
JP2016520058A (ja) 2013-05-07 2016-07-11 ライナット ニューロサイエンス コーポレイション 抗グルカゴン受容体抗体およびその使用方法
CN113683695A (zh) 2013-08-02 2021-11-23 辉瑞公司 抗cxcr4抗体及抗体-药物缀合物
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
CA2943551A1 (en) 2014-03-21 2015-09-24 Teva Pharmaceuticals International Gmbh Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
HUE053287T2 (hu) 2014-04-30 2021-06-28 Pfizer PTK-7 elleni ellenanyag-drog konjugátumok
WO2016020798A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016020799A1 (en) 2014-08-06 2016-02-11 Rinat Neuroscience Corp. Methods for reducing ldl-cholesterol
WO2016034968A1 (en) 2014-09-02 2016-03-10 Pfizer Inc. Therapeutic antibody
US10472424B2 (en) 2014-09-23 2019-11-12 Pfizer Inc. Treatment with anti-PCSK9 antibodies
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
US9758575B2 (en) 2015-04-06 2017-09-12 Yung Shin Pharmaceutical Industrial Co. Ltd. Antibodies which specifically bind to canine vascular endothelial growth factor and uses thereof
MY196625A (en) 2015-04-13 2023-04-23 Pfizer Therapeutic Antibodies and Their Uses
IL257047B1 (en) 2015-07-21 2024-07-01 Dyax Corp A monoclonal antibody that inhibits factor XIIA
DK3350220T3 (da) 2015-09-15 2021-07-12 Scholar Rock Inc Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
WO2017075037A1 (en) 2015-10-27 2017-05-04 Scholar Rock, Inc. Primed growth factors and uses thereof
TWI778491B (zh) 2015-11-30 2022-09-21 美商輝瑞股份有限公司 位點專一性ｈｅｒ２抗體藥物共軛體
WO2017120523A2 (en) 2016-01-08 2017-07-13 Scholar Rock, Inc. Anti-pro/latent myostatin antibodies and methods of use thereof
RU2715703C1 (ru) 2016-03-28 2020-03-03 Сайньюрекс Интернэшнл (Тайвань) Корп. Композиции, содержащие дубильные кислоты и их применение
WO2018055574A1 (en) 2016-09-23 2018-03-29 Teva Pharmaceuticals International Gmbh Treating refractory migraine
EP3515488A1 (de) 2016-09-23 2019-07-31 Teva Pharmaceuticals International GmbH Behandlung von cluster-kopfschmerzen
WO2018064515A1 (en) 2016-09-30 2018-04-05 Academia Sinica Microrna let-7 and transforming growth factor beta receptor iii axis as target for cardiac injuries
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
PL3565592T3 (pl) 2017-01-06 2023-08-21 Scholar Rock, Inc. Leczenie chorób metabolicznych poprzez inhibicję aktywacji miostatyny
RU2770066C2 (ru) 2017-03-02 2022-04-14 Бет Изрейэл Диконисс Медикал Сентер, Инк. Отбор пациентов с головной болью, восприимчивых к антителам, направленным против кальцитонин ген-родственного пептида
AU2018226646A1 (en) 2017-03-03 2019-09-19 Rinat Neuroscience Corp. Anti-GITR antibodies and methods of use thereof
US20230192839A1 (en) 2017-04-12 2023-06-22 Pfizer Inc. Antibodies having conditional affinity and methods of use thereof
CN111052247B (zh) 2017-06-13 2024-06-14 波士顿基因公司 用于由经归一化生物标志物评分鉴定癌症治疗的系统和方法
EP3651799A1 (de) 2017-07-13 2020-05-20 Massachusetts Institute of Technology Targeting des hdac2-sp3-komplexes zur verbesserung der synaptischen funktion
WO2019014710A1 (en) * 2017-07-17 2019-01-24 Monash University ANGIOTENSIN RECEPTOR AGONISTS AND USES THEREOF
US20190048073A1 (en) 2017-07-20 2019-02-14 Pfizer Inc. Anti-gd3 antibodies and antibody-drug conjugates
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
CN112020648A (zh) 2017-10-04 2020-12-01 赫斯佩瑞克斯股份公司 针对癌症个体化疗法的制品和方法
MX2020004381A (es) 2017-10-27 2020-08-20 Pfizer Anticuerpos y conjugados de anticuerpo-farmaco especificos para cd123 y usos de los mismos.
WO2019166946A1 (en) 2018-02-28 2019-09-06 Pfizer Inc. Il-15 variants and uses thereof
US20210196823A1 (en) 2018-06-08 2021-07-01 Pfizer Inc. Methods of Treating Metabolic Disease
US10899826B1 (en) 2018-09-13 2021-01-26 Teva Pharmaceuticals International Gmbh Pharmaceutical compositions for an anti-CGRP antagonist antibody
WO2021028726A2 (en) 2019-07-03 2021-02-18 Bostongene Corporation Systems and methods for sample preparation, sample sequencing, and sequencing data bias correction and quality control
EP4041308A1 (de) 2019-10-07 2022-08-17 University of Virginia Patent Foundation Modulation von lymphgefässen bei neurologischen erkrankungen
WO2021072244A1 (en) 2019-10-11 2021-04-15 Beth Israel Deaconess Medical Center, Inc. Anti-tn antibodies and uses thereof
US20230067811A1 (en) 2020-01-24 2023-03-02 University Of Virginia Patent Foundation Modulating lymphatic vessels in neurological disease
EP4118105A2 (de) 2020-03-09 2023-01-18 Pfizer Inc. Cd80-fc-fusionsprotein und verwendungen davon
US20230181750A1 (en) 2020-05-06 2023-06-15 Crispr Therapeutics Ag Mask peptides and masked anti-ptk7 antibodies comprising such
CA3189590A1 (en) 2020-07-17 2022-01-20 Pfizer Inc. Therapeutic antibodies and their uses
US20220180972A1 (en) 2020-12-04 2022-06-09 Bostongene Corporation Hierarchical machine learning techniques for identifying molecular categories from expression data
WO2022232615A1 (en) 2021-04-29 2022-11-03 Bostongene Corporation Machine learning techniques for estimating tumor cell expression complex tumor tissue
IL309078A (en) 2021-06-23 2024-02-01 Scholar Rock Inc A myostatin pathway inhibitor in combination with a GLP-1 pathway activator for use in the treatment of metabolic disorders
CA3235096A1 (en) 2021-11-17 2023-05-25 Disc Medicine, Inc. Methods for treating anemia of kidney disease
US20230245479A1 (en) 2022-01-31 2023-08-03 Bostongene Corporation Machine learning techniques for cytometry
WO2024015561A1 (en) 2022-07-15 2024-01-18 Bostongene Corporation Techniques for detecting homologous recombination deficiency (hrd)
WO2024138076A1 (en) 2022-12-22 2024-06-27 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69435301D1 (de) * 1993-09-24 2010-08-26 Univ Southern California Verwendung von Angiotensin-II-Analogen zur Gewebewiederherstellung
US6110895A (en) * 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts

Also Published As

Publication number Publication date
CA2364484A1 (en) 2000-09-14
WO2000053211A3 (en) 2001-01-25
EP1158997A2 (de) 2001-12-05
WO2000053211A2 (en) 2000-09-14

Similar Documents

Publication Publication Date Title
AU3734900A (en) Method of promoting myocyte proliferation and myocardial tissue repair
US7118748B1 (en) Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
US7786085B2 (en) Method for treating a patient undergoing chemotherapy
CA2319701C (en) Method of promoting erythropoiesis
AU755943B2 (en) Methods to increase blood flow to ischemic tissue
US6762167B1 (en) Methods for treating a patient undergoing chemotherapy
AU706333B2 (en) Use of angiotensin III and analogs thereof in tissue repair
US6747008B1 (en) Methods for treating and preventing alopecia
AU759285B2 (en) Methods to increase white blood cell survival after chemotherapy
US7122523B2 (en) Methods for inhibiting tumor cell proliferation
US6730775B1 (en) Methods for limiting scar and adhesion formation
AU756156B2 (en) Methods for limiting scar and adhesion formation
US20020049162A1 (en) Methods for inhibiting smooth muscle cell proliferation
WO2001044270A2 (en) Methods for treating and preventing diabetic complications by use of angiotensin-related peptides
EP1292610A1 (de) Verfahren zur behandlung und vorbeugung von alopecia
WO1999039743A2 (en) Method of promoting hepatic cell proliferation
CA2442340A1 (en) Methods for limiting scar and adhesion formation
CA2339328A1 (en) Peripheral-type benzodiazepine receptor associated proteins, cloning, expression and methods of use
MXPA00011112A (en) Methods to increase white blood cell survival after chemotherapy
MXPA00007509A (en) Method of promoting erythropoiesis
CN1187133A (zh) 血管紧张素ⅱ2型受体激动剂在组织修复中的应用

Legal Events

Date Code Title Description
NA Applications received for extensions of time, section 223

Free format text: AN APPLICATION TO EXTEND THE TIME FROM 20001209 TO 20010909 IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN LODGED

NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO ENTER THE NATIONAL PHASE HAS BEEN EXTENDED TO 20010909

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted